Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. 2004 Jul 1 94(1):108-11.Īssociation of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. 2003 Nov 5 42(9):1535-43.Īssociation of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. 2002 Jul 1 90(1):51-4.Īssociation of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. 2002 Apr 23 105(16):1909-13.Ĭomparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial. Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. 2001 Sep 24(9):577-84.Įarly coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. 2000 Dec 15 86(12):1378-9, A5.Ĭombination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. 2000 Jun 15 85(12):1409-13.Īssociation between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. 2000 May 40(5):508-15.ĭegree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction trials). Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. ![]() Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. 1999 Oct 34(4):974-82.ĭeterminants of coronary blood flow after thrombolytic administration. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trialĬirculation. TIMI 10B compared the angiographic efficacy and safety of several doses of TNK with front loaded rtPA in 886 patients with Acute ST Elevation MI <12 hours.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |